New Delhi, July 7 -- Strand Life Sciences, a subsidiary of Reliance Industries Limited, has been granted an Indian patent for its integrated platform that enables early cancer detection from a simple blood test using cell-free DNA (cfDNA) analysis, the company said in a press release on Tuesday.

The patented platform combines high-quality genome sequencing, rigorous quality control, biologically informed methylation and fragmentomic feature extraction, and machine learning to detect cancer and predict its tissue-of-origin from a blood sample.

A key innovation highlighted in the patent is the ability to capture widespread methylation pattern changes across the genome with minimal loss or failure. Such methylation changes are a hallmark o...